Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-08
2008-04-08
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387500, C424S130100, C424S184100, C424S277100, C435S007100
Reexamination Certificate
active
10490535
ABSTRACT:
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
REFERENCES:
patent: 2006/0051349 (2006-03-01), Goldenberg et al.
patent: 2006/0057136 (2006-03-01), Goldenberg
patent: 2006/0194276 (2006-08-01), Krauss et al.
patent: 2007/0003556 (2007-01-01), Tsuchiya et al.
patent: 2007/0059307 (2007-03-01), Popplewell et al.
patent: WO 03/104425 (2003-12-01), None
Short et al (Protein Engineering, 2001. 14:287-296).
Chowdhury, Partha S. et al.; “Improving antibody affinity by mimicking somatic hypermutation in vitro”; 1999,Nature Biotechnology, vol. 17, pp. 568-572.
Frankel, Arthur E.; “Increased Sophistication of Immunotoxins”; 2002,Clinical Cancer Research, vol. 8, pp. 942-944.
Kreitman, Robert J. et al.; “Complete Regression of Human B-Cell Lymphoma Xenografts in Mice Treated with Recombinant Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 at Doses Tolerated by Cynomolgus Monkeys”; 1999,International Journal of Cancer, vol. 81, pp. 148-155.
Kreitman, Robert J. et al.; “Cytotoxic Activity of Disulfide-stablized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias”; 2000,Clinical Cancer Research, vol. 6, pp. 1476-1487.
Kreitman, Robert J. et al.; “Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia”; 2001,New England Journal of Medicine, vol. 345, No. 4, pp. 241-247.
Mansfield, Elizabeth et al.; “Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells”; 1997,Biochem. Soc. Trans., vol. 25, pp. 709-714.
Mansfield, Elizabeth et al.; “Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors”; 1997,Blood, vol. 90, pp. 2020-2026.
Salvatore, Giuliana et al.; “Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display”;2002,Clinical Cancer Research, vol. 8, pp. 995-1002.
Beers Richard
Kreitman Robert J.
Pastan Ira H.
Salvatore Giuliana
Blanchard David J.
Townsend and Townsend / and Crew LLP
Tungaturthi Parithosh K.
United States of America as represented by the Secretary of the
LandOfFree
Mutated anti-CD22 antibodies with increased affinity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutated anti-CD22 antibodies with increased affinity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutated anti-CD22 antibodies with increased affinity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3935144